























































































































































































































Tweaking mesenchymal stem/progenitor cell immunomodulatory properties with viral 
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AAV: adeno-associated viruses 
Adv: adenoviral 
ALS: amyotrophic lateral sclerosis 
AT: adipose tissue 
AT-MSCs: adipose tissue-derived MSCs  
BM: bone marrow 
CNS: central nervous system 
DC: dendritic cell 
EAE: experimental autoimmune encephalomyelitis 
FDA: Food and Drug Administration 
FGF: fibroblast growth factor 
GVHD: graft-versus-host-disease 
HGF: hepatocyte growth factor 
IL: interleukin 
IL-1Ra: interleukin-1 receptor antagonist 
IFN-γ: interferon-γ  
IRI: ischaemic reperfusion injury 
ISCT: Mesenchymal and Tissue Stem Cell Committee of the International Society for 
Cellular Therapy 
Kbp: Kilobase pairs 
LV: lentiviral 
MS: multiple sclerosis 
MSCs: mesenchymal stem cells 
NK: natural killer 
SDF-1: stromal derived growth factor 
SLE: systemic lupus erythematosus 
SOT: solid organ transplantation 
TGF-β: transforming growth factor-β 
TNF-α: tumor necrosis factor-α  
Th: T helper lymphocytes 
T-reg: regulatory T-cell 
UC: umbilical cord 
























































































































































































































































































































































































UCB: umbilical cord blood 
UC-MSCs: umbilical cord derived MSCs 
UCB-MSCs: umbilical cord blood derived MSCs 
VEGF: vascular endothelial growth factor 
WJ: Wharton's Jelly 
WJ-MSCs: Wharton's Jelly derived MSCs 
Wt: wild type 



























































































































































































































































































































































































Mesenchymal Stem Cells (MSCs) can be found in various body sites. Their main role is to 
differentiate into cartilage, bone, muscle and fat cells to allow tissue maintenance and repair. 
During inflammation, MSCs exhibit important immunomodulatory properties that are not 
constitutive but require activation, upon which they may exert immunosuppressive functions. 
MSCs are defined as “sensors of inflammation” since they modulate their ability of interfering 
with the immune system both in vitro and in vivo upon interaction with different factors. 
MSCs may influence immune responses through different mechanisms, such as direct cell-to-
cell contact, release of soluble factors, and through the induction of anergy and apoptosis. 
Human MSCs are defined as plastic-adherent cells expressing defined surface molecules. 
Lack of MHC class II antigens makes them appealing as allogeneic tools for the therapy of 
both autoimmune diseases and cancer. MSC therapeutic potential could be highly enhanced 
by the expression of exogenous cytokines provided by transduction with viral vectors. In this 
review, we attempt to summarize the results of a great number of in vitro and in vivo studies 
aimed at improving the ability of MSCs as immunomodulators in the therapy of autoimmune, 
degenerative diseases and cancer. We will also compare results obtained with different 
vectors to deliver heterologous genes to these cells. 


























































































































































































































































































































































































MSCs were isolated from the bone marrow (BM) for the first time in the 1970’s by 
Friedenstein [1]. The term "Mesenchymal Stem Cell" was introduced by Caplan in the 1980’s 
after discovering MSC ability to differentiate into mesodermic cells: chondrocytes, tenocytes 
and myoblasts [2]. It was recognized that MSCs meet adult stem cell criteria, such as self-
renewal and differentiation potential [3]. Soon after their discovery, the problem arose as to 
whether the term “stem cell” was appropriate, since only a small fraction of cultured MSCs 
qualify as stem cells according to the generally accepted criteria [4]. In 2005, the new 
expression “multipotent mesenchymal stromal cells” (maintaining the acronym MSCs) was 
proposed to describe these fibroblast-like plastic-adherent cells. It was also proposed to use 
the term “MSCs” only for cells that meet specified stem cell criteria [4]. Caplan defined 
MSCs as “the sentinels and safe-guards of injury”. He suggested that the main role of MSCs 
is protection from injuries and proposed to change their name into “Medicinal Signaling 
Cells” to keep the same acronim [5]. 
The discovery of a pool of multipotent cells present virtually in every tissue of adult animal 
raised great enthusiasm in the hope they could be used in cell therapy, without limitations by 
those ethical concerns that have hindered the use of embryonic stem cells [6]. 
Among their properties, MSCs also exhibit immunomodulating ability. Their application in 
treating several pathologies has been largely investigated both in preclinical models and in 
clinical trials [https:\\clinicaltrials.gov]. Currently, naïve hMSCs are employed in a large 
number of clinical trials successfully and, as a result, the first cell-based therapy based on 
allogenic MSCs-derived drug has been approved by the Food and Drug Administration (FDA) 
[7]. 
Since 2002, numerous attempts at improving MSC immunomodulatory potential by 
engineering them with various cytokines have been carried out [8–10]. Several viral vectors 
have been used to deliver heterologous genes in vitro and in vivo to engineer MSCs. 
Adenoviral (Adv) and retroviral vectors were used extensively to tweak MSC properties in 
experimental settings and most studies agree that such procedures are likely to ameliorate 
MSCs as cells in therapy [11] [see Tables 2 and 3]. Unfortunately, all these studies are at a 
preclinical stage, therefore the major future goal will definitely be to test modified MSCs in 
clinics. 

























































































































































































































































































































































































1. MSC generation and innate properties 
 
1.1 Sources 
MSCs were initially isolated from the BM by a low-yield invasive process [12,13]. For this 
reason, other sources of cells were explored. Presently, MSCs may be derived from almost 
every tissue [14,15]: adipose tissue (AT) [16], lymphoid organs (thymus and spleen) [17], 
peripheral blood [18], endometrium and menstrual blood, scalp tissue, periodontal ligament, 
as well as placenta, amniotic fluid [19], umbilical cord blood (UCB) [20] and Wharton's Jelly 
(WJ) [21,22]. The therapeutic effect of hMSCs depends on many parameters such as tissue 
source of isolation, the methods of purification and the animal model used to assessed their 
efficacy; indeed, encouraging results in animal models not always meet expectations in 
clinical trial, as discussed later [23]. Thus, even if MSCs derived from different sources may 
meet generally accepted criteria, they may differ in proliferation rate and differentiation 
potential [24]. 
Sources alternative to BM were also explored to attain higher proliferative potential and a 
more accessible source [15,19]. Currently, one of the main sources of MSCs is AT because it 
is readily available, the harvest procedure is less invasive than BM aspiration and the yield of 
MSCs is very high [16]; indeed, AT has 500 times richer in MSCs than BM [25]. AT-derived 
MSCs (AT-MSCs) proliferate rapidly in vitro and show low levels of senescence even after 
months of in vitro culture [26]. Nevertheless, isolation and expansion of AT-MSCs is 
somewhat less prone to automation in bioreactors. 
Wharton's jelly derived MSCs (WJ-MSCs) are also often used, since they are abundantly 
available after childbirth. Compared to the other sources, they are ontogenically primitive 
[21]. Most Authors agree on the fact that they have higher proliferative potential compared to 
both AT and BM [15]. In contrast, Bortolotti et al. showed that hBM-MSCs grow faster in 
vitro and have higher proliferative potential than AT-MSCs even though they only survive to 




MSCs are generally characterized by expression of CD105 (SH2), CD73 (SH3 or SH4), 
CD90, CD166 (VCAM), CD44, CD 54/102 (ICAM1-2) CD 157, CD49, and Stro-1, and lack 
of CD11b, CD14, CD31 and CD45 (which identify hematopoietic or endothelial cells) [12]. 
























































































































































































































































































































































































Phenotypic markers alone are not sufficient to identify hMSCs unequivocally, because the 
former can be expressed by other cell types as well; furthermore, during culture expansion, 
phenotypic marker expression can change, probably due to ageing of cells [27]. Different 
tissue origin, procedures of isolation, and culture conditions of MSCs in different laboratories 
produce heterogeneity of cell populations obtained [23]. This makes it hard to compare the 
biological properties and experimental outcomes in cell therapy trials. Therefore, the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy (ISCT) proposed a set of standards to define human MSCs unambiguously [28]. 
According to such criteria, MSCs are defined as a plastic-adherent population (when cultured 
in standard conditions), phenotypically expressing CD105, CD73, CD90 for more than 95% 
of the population 
 
and lacking expression of CD45, CD34, CD11b or CD14, CD 19 or CD79a, 
and HLA class II (≤2% positive). Moreover, MSCs must be able to differentiate to osteocytes, 
adipocytes or chondrocytes when cultured in appropriate differentiation media. These criteria 
apply only to human MSCs because cells derived from other species (such as rat and mouse) 
show different phenotypic markers [29]. 
All MSCs show similar phenotypes and functional features [15]. However, there are a number 
of differences that depend on their micro-environmental niche, original local function 
(stromal support of hematopoiesis in the BM vs immune homeostasis by AT), and ontogenetic 
age (birth-associated vs adult) [15]. For instance, CD106 is significantly reduced on AT-
MSCs compared to other MSCs [15]. Certain differences in potency may also exist: while 
AT-MSCs have multi-lineage differentiation potential in vitro and in vivo [30], there are 
conflicting reports regarding cord tissue-derived MSCs. Mattar and Karagianni reported that 
UCB-MSCs have significantly less adipogenic differentiation capacity [31]. Very recently, 
Reinisch also showed that only BM-MSCs are capable to form a functional hematopoietic 
niche [32]. 
All studies agree on the ability of all MSCs carry out immunomodulation; in this respect, AT-
MSCs proved to be more efficient than MSCs from other sources [24]. At present, 
comparative studies on MSCs do not consider the variables affecting their 
immunomodulatory efficacy, but only compare properties of cells in vitro, such as phenotypic 
markers, multipotency, and angiogenic ability ex vivo [23]. 
In conclusion, there is no consensus on the best source or culture method for MSC isolation 
because cells vary in their therapeutic efficacy depending on the model considered [6]. 
 
1.3 Properties 

























































































































































































































































































































































































BM-MSCs support hematopoiesis by producing extracellular matrix components, such as 
cytokines and growth factors, in BM and most other tissues. Their main physiological role is 
to promptly mobilize and differentiate in response to signals of pathological or traumatic 
nature [33]. They actively respond to stress and injury, and can promote angiogenesis and 
regeneration. 
Recently, pericytes were recognized as MSCs, i.e. perivascular cells forming a unique niche, 
appointed to maintain the integrity of blood vessels. Pericytes can indeed be isolated from the 
BM and exhibit the same characteristics of MSCs [34,35]. They are positive for phenotypic 
markers CD10, CD13, CD44, CD73, CD90, CD105 and negative for CD56, CD106, CD133 
[36]; in addition, they are able to differentiate into MSC lineages both in vitro and in vivo 
[14,36]. Perivascular location of MSCs is essential for their fast recruitment at the site of 
damage or inflammation. 
MSCs downregulate activated immune cells and reduce damage to the site of inflammation, 
therefore they may be considered one of the most important mechanisms of defence against 
excessive autoimmune reactions [5]. When stimulated by environmental signals of 
inflammation, MSCs release several molecules suppressing the immune response so that they 
can escape immune surveillance and easily migrate towards the site of injury [5]. Therefore, 
they can have many applications in immunotherapy, for example in the treatment of 
degenerative and inflammatory pathologies. Immunomodulatory properties have been widely 
demonstrated for all MSC populations, independently of their source of isolation, both in 
preclinical and clinical trials. However, AT-MSCs showed stronger effects compared to 
others models [24,37]. Since interaction of MSCs with cells of the immune system is very 
complex and often mutually dependent, many Authors disagree on the mechanisms involved 
in immunomodulation; for this reason, the ISCT has also proposed standardized guidelines 
and protocols for their immunological characterization [38]. 
As mentioned above, MSCs may suppress or stimulate immunity depending on their 
surrounding. MSC immunomodulatory ability is not constitutive but requires activation in a 
pro-inflammatory environment [6]. It has been shown that interleukin-1 (IL-1), interferon-γ 
(IFN-γ), and tumor necrosis factor-α (TNF-α) are involved in the priming of MSCs, which 
consequently interact with cells of both innate and adaptive immunity [6,7]. MSCs may alter 
cytokine secretion by dendritic cells (DCs) preventing their maturation and activation [39,40], 
suppress T cell and natural killer (NK) cell proliferation and their cytokine production [41] 
and B cell functions [41,42]. 
























































































































































































































































































































































































MSCs may influence immune activity through different mechanisms, such as direct cell-to-
cell contact, release of soluble factors, and through the induction of anergy and apoptosis [7]. 
Interaction with the immune cells takes place via expression of a large number of adhesion 
molecules, like VCAM-1, ICAM-1, LFA-3, HLA and MHC-I, expressed on MSC surface 
[12,43]. Because they lack MHC-II and costimulatory molecules such as CD40, CD80 or 
CD86, MSCs are considered "immuno-priviledged" cells and good candidates for allogeneic 
transplantation [44], with the caveat that, in inflammatory conditions, up-regulation of MHC-
II can increase their immunogenicity [45]. However, MSCs immunogenicity observed in 
certain studies may be due to the use of undefined serum or plasma for cell culture, rather 
than to MSCs themselves [46]. Currently, the question on MSC immunogenicity is being 
debated and under investigation. 
MSCs release many soluble factors, including transforming growth factor-β (TGF-β), 
hepatocyte growth factor (HGF) [47], nitric oxide [48], indoleamine 2,3-dioxygenase [49], 
prostaglandin E2, interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1Ra), 
interleukin 6 (IL-6), leukocyte inhibitory factor, HLA-G, hemeoxygenase, TNF-α, and many 
others. A pivotal role is played by IL-10 that supports the differentiation of regulatory T cells 
(T-regs). The ability of MSCs to induce T-regs has been observed both in vitro and in vivo [6, 
50–52]. MSCs activate macrophages derived from circulating resident monocytes and initially 
polarize them to M1 profile [6, 53]. Upon the influence of inflammatory cytokines released by 
M1 macrophages, MSCs start skewing macrophages towards the M2 subtype by a feedback 
mechanism [54]. 
 
2. Innate immunomodulation properties of MSCs and their exploitation in clinic 
 
The ability of MSCs to tightly interact with immune cells has been explored to treat many 
diseases where a pivotal role is performed by the immune system. Here we summarize the 
principal approaches. 
 
2.1 Immunomodulation in the therapy of autoimmune and degenerative diseases 
 
The first pioneering study on the effect of MSCs administration in vivo was performed more 
than 10 years ago for the treatment of graft-versus-host-disease (GVHD), a syndrome given 
by activation of donor T cells against recipient tissues after BM transplantation [55]. Severe 
acute GVHD is often refractory to immunosuppressants and has been reported to have an 
























































































































































































































































































































































































overall 2-year survival of 5–30% [56]. In this regard, MSCs represent the main alternative to 
drugs. In the study mentioned above, haploidentical third-party MSCs were compassionately 
administered to a 9-year-old boy with steroid-resistant grade-IV GVHD, who completely 
healed after a year. The success of the therapy opened the way to clinical trials for treatment 
of GVHD with MSCs. 
At present, phase II/III multicenter clinical trials have confirmed the efficacy of MSC 
treatment on adult and pediatric patients affected by steroid-resistant GVHD both in the USA 
and in Europe. Most importantly, third-party-derived MSCs were shown to be safe as 
allogeneic cells [57,58]. As a result, the drug Prochymal
TM
 (Osiris Therapeutics Inc., 
Columbia, MD, USA), based on allogenic MSCs derived from the BM of adult donors, was 
approved by the FDA to treat acute GVHD. Currently, Prochymal
TM
 is being tested in two 
phase-III clinical trials on newly diagnosed patients (NCT00562497) and on steroid-refractory 
GVHD (NCT00366145). While the effect of MSC administration in acute GVHD has been 
demonstrated, their efficacy against chronic disease still needs further investigation: so far, 
chronic patients seem to be less responsive [59,60]. Therefore, efficacy of MSC therapy for 
the treatment of chronic GVHD is still unclear. 
After the extraordinary results obtained in acute GVHD, MSC therapy was also tested in the 
field of solid organ transplantation (SOT) as an alternative to immunosuppressive drugs, with 
the aim to prevent acute graft rejection and failure. Indeed, there are major concerns about the 
currently used immunosuppressants; their side effects vary from acute and chronic 
nefrotoxicity, hypertension, hepatotoxicity and neurotoxicity, as well as an increased risk 
gastrointestinal disorders and diabetes [61–63]. Moreover, SOT is often followed by 
ischemia-reperfusion injury (IRI) that, in turn, causes systemic inflammation. This event can 
lead to delayed function and primary dysfunction of graft. In the past, several studies 
performed in preclinical models showed the ability of MSCs to reduce IRI, preventing graft 
rejection, and to promote immunotolerance in SOT [64–68]. Since then, clinical trials have 
been carried out where MSCs proved to be successful alone or in association with low doses 
of immunosuppressive drugs in kidney transplantation [69,70]. Currently, a phase I/II clinical 
trial is testing MSCs for liver transplantation. However, preliminary results obtained in 
clinical trials are less satisfactory than expected on the basis of the results on animal models. 
MSCs have been used for the treatment of other autoimmune diseases, a category of 
pathologies where malfunctioning of the immune system is a determining factor. 
Administration of MSCs appears to be a promising therapy also in pancreatic islet 
transplantation for the treatment of type-I diabetes, an autoimmune disease triggered by the 
























































































































































































































































































































































































immune response against autoantigens of β-cells. The effects of MSCs have been largely 
studied and clear evidence showed that MSCs can suppress autoimmunity against islets, 
support neo-angiogenesis in damaged microvasculature of islets and prevent acute rejection 
[67,71,72]. At present, more than 20 phase I/II clinical trials employing allogeneic MSCs or 
Prochymal
TM
 for the treatment of diabetes are underway. 
MSCs have been also tested in Crohn's disease, a chronic condition where the immune system 
attacks the gastrointestinal tract. A phase-I clinical trial has been performed by infusion of 
autologous MSCs in patients that did not respond to conventional treatment. Results showed 
an improvement of the disease with no significant adverse events either during BM harvesting 
or after MSC infusion; only mild allergic reactivity was observed in one patient probably due 
to dimethylsulfoxide used to cryopreserve cells. The administration of autologous BM-MSCs 
seems to be a safe and feasible therapy for the treatment of refractory Crohn's disease [73]. At 
the time of writing, Prochymal
TM
 is being tested in Crohn’s disease in a phase-III clinical trial 
(NCT01233960). Since Crohn's disease is often associated with the formation of perianal 
fistulae, autologous AT-MSCs have also been employed in their treatment with promising 
results and a phase-II clinical trial is being carried out [74]. 
Multiple Sclerosis (MS), a neurodegenerative pathology of the central nervous system (CNS) 
characterized by focal demyelination, neuronal damage, glial cell activation and massive 
infiltration of immune cells, is thoroughly studied [75]. In the pathogenesis of MS, the 
inflammatory response is associated to an autoimmune reaction where both cellular and 
humoral components are activated against antigens of the CNS [76]. The neurodegenerative 
process, instead, is responsible for increasing disability in MS, because it induces neuronal 
and axonal loss and leads to brain atrophy [77]. MSC transplantation has been proposed as a 
cell-based therapy for MS, in alternative to the one in use. In experimental models, MSCs 
seem to protect CNS from autoimmune demyelination; the observed therapeutic effect is 
thought to be mainly due to release of cytokines and chemokines, which suppress 
inflammation and enhance proliferation, migration and differentiation of endogenous 
stem/progenitor cells [78] 
Despite the promising results derived from experimental animal models of MS, the efficacy of 
MSC treatment in clinical trials is less evident. In a pilot study performed on 10 patients 
affected by MS, only 6 showed improvement in the disease as a result of intrathecal injection 
of MSCs; in addition, 12 months after treatment, no improvement was evident by magnetic 
resonance [79]. Furthermore, in a phase-I and, more recently, in a phase-II clinical trial, 
intrathecal administration of MSCs induced modest improvement of only certain specific 
























































































































































































































































































































































































parameters related to vision impairment [80,81]. 
The most encouraging results have been obtained in the treatment of systemic lupus 
erythematosus (SLE), an autoimmune inflammatory disease with multiorgan involvement 
including renal, cardiovascular, neural, musculoskeletal, and cutaneous systems. SLE is often 
refractory to conventional therapies based on corticosteroid administration [82]. Recently, 
SLE has been demonstrated to be a stem cell disorder caused by a defect in BM 
microenvironment [83]. Accordingly, MSCs derived from patients with SLE exhibited 
impaired proliferation, differentiation, and immune modulation capacities [84]. Moreover, the 
main features of SLE are alteration in cytokine homeostasis and defects in T-reg development  
[85]. In the light of such premises, allogenic MSC transplantation seems the best approach for 
treatment of the disease. In a pilot study performed on SLE patients refractory to standard 
treatment, administration of allogeneic MSCs proved to ameliorate renal functions and restore 
T-reg cells, with no side effects observed [86]. 
Controversial results have been obtained by employing MSCs in preclinical models of 
rheumatoid arthritis, a systemic autoimmune disorder mediated by T cells and characterized 
by chronic inflammatory synovitis and progressive joint destruction. Alteration of auto-
reactive T cells and inflammatory cytokines such as TNF-α play a pivotal role in the 
pathogenesis of the disease [87–89]. Currently no clinical trials have started. 
In contrast, MSC therapy has proved clearly effective in the treatment of other inflammatory 
disease, such as stroke [90,91], asthma [51], allergic rhinitis [92], lung injury [93], colitis, 
sepsis. In this context, experiments in mice showed that MSC administration in murine 
models of experimental colitis and sepsis reduced the severity of the disease by inducing M2 
polarization and the secretion of anti-inflammatory cytokines [94–96]. MSC therapy has been 
also tested for the treatment of amyotrophic lateral sclerosis (ALS) a neurodegenerative 
disease which rapidly induces loss of motor neuron function. The pathophysiology of the 
disease is poorly understood but it is believed that the immune response could also play a 
crucial role. In a phase-I clinical trial performed with 10 patients, BM-MSCs were 
transplanted into the spinal cord: no side effects were observed [97]. In another phase I/II 
clinical trial, involving both ALS and MS patients, autologous MSCs were administered both 
intrathecally and intravenously to maximize homing to the CNS. In ALS patients, functional 
improvement was evident and only mild side effects were observed, probably due to residual 
dimethylsulfoxide. Moreover, an increase of CD4+, CD25+, Foxp3+, and T-regs and 
downregulation of activated lymphocytes and antigen-presenting cells were reported, whereas 
T-regs are normally reduced in patients with rapid disease progression [98,99]. The excellent 
























































































































































































































































































































































































outcomes and lack of safety concerns pave the way for other phase-II trials. 
 
2.2 Immunomodulation in the therapy of cancer 
 
MSCs are also able to adopt a pro-inflammatory phenotype [6,53]: they are able to recruit 
neutrophils through the production of chemokines, and enhance their pro-inflammatory 
activity through the production of IL-6, IL-8, GM-CSF and migration inhibitory factor 
[100,101]; in vivo murine MSCs strongly increase T cell proliferation [48,102,103]. Since 
MSCs exhibit immunostimulatory properties, the application of MSCs in anticancer therapy 
has been explored. MSC homing ability towards the sites of injury is well known, but several 
studies demonstrated that they are also driven toward tumor sites and incorporated within the 
connective tissue stroma of tumors after intravenous injection [104]. Both in vitro and in vivo 
tests proved that MSCs home into glioma, both after intraarterial and local intracranial 
delivery. This process is mediated by growth factors and chemokines [104,105]. MSCs 
injected in vivo have been shown to distribute mostly at the border between cancerous and 
normal parenchyma and also uniformly infiltrate into the tumor bed while no MSCs were 
observed in healthy organs [8,104–106]. At present, the mechanisms involved in MSC 
migration are unknown, but two possible alternatives have been hypothesized: homing of 
MSCs may be favoured by the secretion of chemokines/cytokines by tumor tissues; 
alternatively, the interaction of cytokines or chemokines with their receptors might induce 
migration of MSCs towards the tumor microenvironment. Several studies have suggested that 
both cytokines, such as vascular endothelial cell growth factors (VEGF), TGFs, fibroblast and 
platelet-derived growth factors, monocyte chemoattractant, protein-1, and IL-8 [106,107] and 
adhesion molecules, such as β1- and β2-integrins and L-selectin, could be involved [108,109]. 
Furthermore, MSCs express several receptors like CXCR4, CX3CRl, and many others, which 
interact with their specific ligands [110]. CXCR4 and stromal cell-derived factor-1 (SDF-1) 
seem to play the main role, in the migration of MSCs towards the tumor site and in the 
pathology of glioma [111]. The extraordinary ability of MSCs to “sense tumor” has been 
exploited to deliver several anti-cancer gene products to tumor cells in vivo [8, 112]; 
particularly 3 of the gene products have received the most attention: IL-2 [106], IFN-β [8, 
112], and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [113]. 
Although MSCs look promising for cancer therapy, their antitumor effects are still 
controversial. Some Authors showed that unmodified MSCs inhibit tumor growth and 
angiogenesis [114,115], while others report that MSCs support tumor development and 
























































































































































































































































































































































































metastasis [116]. Consequently, further preclinical studies are warranted before clinical trials 
can be started. 
 
3. Enhancing MSC immunomodulatory properties by exogenous gene transfer 
 
The therapeutic potential of MSCs can be altered and routed by gene delivery. Indeed, 
delivery and expression of specific exogenous genes can yield MSCs releasing soluble 
factors, expressing specific receptors, conferring migratory ability or actions in response to 
specific stimuli, etc. 
The idea of using exogenous cytokines to, for instance, stimulate antitumor responses is not 
new. Direct administration of cytokines was attempted twenty years ago [117], whereas 
delivery of IL-2, IL-12, IFN-β and yet other cytokines by viral vectors is more recent 
[118][202]. Both strategies have drawbacks: because of difficulties in reaching tumor sites 
and their short half-lives, free cytokines need to be inoculated at high doses and repeatedly, 
thus increasing their toxicity. In vivo injection of viral vectors, on the other hand, does not 
ensure specific targeting and is associated with safety concerns [118]. Thus, local cytokine 
delivery through engineered MSCs is a more promising, safe, and effective approach. 
The main obstacle to the development of such MSC-based therapeutic approaches is the 
inherent resistance of MSCs to most transfection and transduction strategies. Transfection, 
which implies the use of plasmids, transposons, RNA or other molecular constructs can be 
achieved by treating cells with microprecipitates of nucleic acid-Calcium complex, 
electroporation, liposomes, etc. These methods have become routine and are successfully used 
on a wide variety of adherent and suspension culture cells [119]; further, since molecular 
constructs do not integrate into the host cell genome, or are silenced/eliminated a few days 
after transfection, this approach presents a highy safe profile and is, therefore, preferable for 
clinical use. Unfortunately, the very poor performances shown with MSCs make these 
methods inapplicable for MSC-based therapeutic approaches. 
Gene transfer in MSCs has been mostly carried out with vectors derived from Adv, adeno-
associated viruses (AAV), and lentiviruses (LV). As detailed in Table 1, these vectors have 
pros and cons and provide a wide choice of approaches ranging from transient to permanent 
modification of cells, constitutive or inducible expression of the transgene – i.e. the 
heterologous gene delivered by the vector -, delivery of one or more transgenes, etc. Detailed 
description of Adv, AAV, and LV vectors is available elsewhere [120]. Here we focus on 
same characteristics with particular reference to MSC transduction. 

























































































































































































































































































































































































3.1 Adenoviral vectors 
 
Adv vectors, a schematic is available in Figure 1A, transduce dividing and non-dividing cells. 
Their DNA genome persists as an episome for a few days, ensuring transient, high level  
expression of the transgenes. For this feature Adv vectors are considered safe but gene 
modification is short-lasting and is not transmitted to progeny cells. For these reasons, Adv 
vectors are used for vaccination purposes or transient cell manipulation [120–122]. 
MSCs lack the Adv receptor and are therefore basically resistant to Adv vector transduction 
[123]. High vector/cell ratio is therefore necessary to transduce hBM-MSCs possibly causing 
various toxic effects and strong immune reactions in vivo [8]. Ongoing studies to improve 
efficiency of MSC transduction aim to generate recombinant vectors bearing other viral 
receptors [124–127] or using cationic polymers, chelating agents, or small peptides to reduce 
electrostatic repulsions [128–130] 
 
3.2 Adeno-associated viral vectors 
 
Parental AAV viruses infect a wide range of cells in vivo and insert their viral genome in a 
specific and harmless site of the cellular genome. AAV vectors transduce both dividing and 
non-dividing cells, exhibit minimal immunogenicity and toxicity but, having a small genome, 
can transport minute amounts of heterologous genetic material and, owing to deletion of a 
substantial part of the viral genes, have lost the capacity to integrate into the host cell genome 
(Table 1). Despite these limitations, AAV vectors elicit long-term transgene expression in 
vivo and are used in large number of clinical trials. 
Initial studies have shown that AAV vector transduce MSCs without altering their 
multipotential ability but establish low level of transgene expression [131–133] have shown 
that there is ample room for improvement [132,134–137]. 
 
3.3 Lentiviral vectors 
 
LV vectors transduce both quiescent and dividing cells and integrte teir vector genome into 
the host cell genome thus ensuring long-lasting expression of the transgene [138] For these 
and other features shown in Table 1 are the most used vectors for gene therapy. Transduction 
of MSCs with LV vectors has been extensively investigated [11,139]. In their simplest 
























































































































































































































































































































































































version (i.e. single transgene controlled by a standard cytomegalovirus immediate early 
promoter) and using a low vector/cell ratio, LV vectors transduced over 25% human BM-
MSCs and expressed the transgene for over 5 months in vitro [139]. Also, transduction did 
not alter MSC phenotype, in vivo homing, viability, proliferation of cells, nor ability to 
differentiate into adipocytes and osteocytes[11,140,141]. Like AAV vectors, MSC 
transduction went up to 95% with LV vectors bearing different constitutive or inducible 
promoters [11,142], using synthetic polymers to reduce electronic repulsion [140] and/or, a 
second transgene to sort transduced cells [143,144]. High efficiency of transduction and, the 
capacity to carry two or more transgenes make LV vectors the system of choice for MSC 
transduction as it permits, for instance, to deliver reporter genes to monitor localization, 
viability, and, differentiation pathway of the engineered cells [9,145] 
 
4. Alteration of MSCs immunomodulation properties by gene transfer 
 
MSCs have been transduced with the vectors described above and carrying transgenes 
capable of enhancing or counteracting immunosuppressive properties of naïve MSCs. In the 
following sections, we summarize the main studies performed and the results obtained. 
 
4.1 Enhancing MSC immunosuppression 
These studies are based on the delivery of the following anti-inflammatory cytokines 
(also enlisted in Table 2). 
 
 
Interleukin-1 receptor antagonist 
 
IL-1α and IL1-β play a pivotal role in chronic inflammation and in the activation of innate 
immunity. IL-1α is released by a variety of cells undergoing necrosis, for example after 
epithelial damage, myocardial infarction, stroke, tumour decay or acute renal failure and may 
be considered an “alarmin”, since it induces production of IL-1β, TNF-α and IL-6 [146,147]. 
IL-1β is released by monocytes, macrophages, neutrophils and DCs. It is a potent 
proinflammatory cytokine locally causing vasodilatation, granulocytes chemotaxis into 
damaged tissue and expression of prostaglandins. IL-1β also brings about activation of the 
proinflammatory T helper (Th) 17 cells and the development of chronic inflammation [146]. 
IL-1β plays a pivotal role in the pathophysiology of various inflammatory conditions, such as 
























































































































































































































































































































































































rheumatoid arthritis, prosthetic aseptic loosening of arthroplasty, acute liver failure, hereditary 
autoinflammatory diseases, rheumatoid arthritis, osteoarthritis, type 2 diabetes mellitus, 
cardiovascular disease and many others [146,148,149]. 
The Interleukin -1 receptor antagonist (IL-1Ra) can be considered an antagonist of the pro-
inflammatoy cytokines IL-1α and IL1-β, since it binds their receptor blocking IL-1α and IL-
1β signaling [150]. IL-1Ra is expressed in all tissues and is present in serum at high levels. It 
is able to prevent uncontrolled activation by IL-1β both in vitro and in vivo, thereby reducing 
inflammation, but high concentrations are required [151]. In healthy conditions, there is a 
balance between the proinflammatory activities of IL-1α and IL-1β and the ability of IL-1Ra 
to control their production; alteration of this equilibrium can induce inflammatory diseases 
[150]. IL-1Ra could be valuable to treat inflammatory diseases; indeed, the infusion of 
exogenous IL-1Ra is being evaluated in clinical trials against GVHD and MS. 
MSCs are also able to secrete IL-1Ra [152]. They have an improved anti-inflammatory effect 
compared to administration of exogenous IL-1Ra [153]. Moreover, combined therapy with 
IL-1Ra and MSC is more efficient than the use of the two separate treatments [154]. Thus, 
engineering of MSCs with IL-1Ra (MSCs/IL-1Ra) potentiate IL-1Ra release. BM-MSCs/IL-
1Ra have been tested both in vitro and in in vivo models of several diseases (Table 2). hBM-
MSCs transduced by Adv vectors expressing IL-1Ra in association with HGF (hBM-
MSCs/HGF/IL-1Ra) or VEGF (hBM-MSCs/VEGF/IL-1Ra) have been studied in islet 
transplantation for the treatment of Type-I diabetes [155,156]. Because IL-1β plays a key role 
in the loss of islet viability after transplantation [157], systemic administration of MSCs or 
their local injection in transplanted islets partially reduces inflammation, promotes 
revascularization and supports graft survival. However, they were not enough to completely 
prevent apoptotic cell death and more than 70% of islets were lost in the first weeks after 
transplantation [158,159]. It was demonstrated that engineered cells were able to secrete high 
levels of IL-1Ra and HGF/VEGF and, by acting in synergy, the cytokine expressing MSCs 
prevented apoptosis of islet cells and improved islet engraftment, thus supporting long-lasting 
normoglycaemia [155]. 
IL-1β hampers cartilage and bone regeneration [146]; together with TNF-α, it hinders MSCs 
differentiation to chondrocytes [160]. Accordingly, an in vitro study demonstrated that MSCs 
engineered with IL-1Ra by an inducible LV vector, were able to support MSCs chondrogenic 
differentiation also in the presence of IL-1β [161]. The effect of MSCs therapy combined to 
exogenous administration of IL-1Ra resulted effective also in the treatment of acute liver 
failure, a pathology characterized by severe liver cell damage [162]. MSCs/IL-1Ra have not 




























































































































































































































































































































































































Interleukin-10 (IL-10), a pleiotropic cytokine, is considered to play a key role in quenching 
immune responses and is one of the most important soluble factors secreted by MSCs [163]. 
IL-10 has multiple immunoregulatory effects, such as down-regulation of MHC-II and 
costimulatory molecule expression; inhibition of DC maturation, function, and secretion of 
pro-inflammatory cytokines and chemokines [164]. In vivo, IL-10 secreted by naïve MSCs 
improved organ function and survival in a sepsis experimental model. 
Since genetic delivery of IL-10 was shown to improve allograft survival in many animal 
models of heart or liver transplantation [165,166], MSCs genetically engineered with IL-10 
were tested in a rat model of orthotopic liver transplantation. The injection of MSC/IL-10 
significantly improved graft survival by increasing the expression of T-reg cell-associated 
cytokines (IL-10 and TGF-β1), and decreasing the expression of Th-17 cell-related cytokines 
(IL-17, IL-6, IFN-γ, TNF-α and IL-23) [167]. Indeed, it was demonstrated that T-regs play an 
important role in inhibiting acute graft rejection and in the prevention of autoimmune diseases 
[168,169]. The ability of MSC/IL-10 to prevent liver transplant rejection was higher than the 
effect observed with naïve MSCs. 
In vitro studies were performed with hWJ-MSCs transduced with human IL-10 (hIL-10) or 
Epstein-Barr virus IL-10 (v-IL10) [9,170]. vIL-10 is similar to hIL-10 but only has the 
immunosuppressive domain of the cytokine [169–173]. hWJ-MSC/vIL10 showed enhanced 
ability compared to naïve MSCs to release IL-10 in solution and increased 
immunosuppressive properties. They were able to act both on innate immunity by decreasing 
TNF-α production by monocytes upon LPS stimulation, and on adaptive immunity by 




Interleukin-4 (IL-4), like IL-10, is a pleiotropic cytokine, involved both in innate and adaptive 
immunity. IL-4 is secreted by Th2 cells together with IL-10 and IL-13 to quench 
inflammation. It is also able to stimulate proliferation of B and T cells and foster 
differentiation of naïve Th0 into Th2. Besides, IL-4 stimulates T-reg proliferation and 
chemotaxis [174]. 
























































































































































































































































































































































































Exogenous administration of IL-4 has been studied in several experimental models of 
autoimmunity where Th2 cells mediate disease remission, such as experimental autoimmune 
encephalomyelitis (EAE) as a model for MS [175–177]. Exogenous administration of IL-4 
was shown to ameliorate EAE in mice through a Th1 to Th2 shift, but repeated administration 
of high doses of IL-4 were required [178]. Subsequently, it has been demonstrated that 
injection of recombinant plasmid, Adv and herpes simplex viral vectors encoding IL-4 in 
mice with EAE favoured remission of the disease [175,179–181]. Following these studies, 
AT-MSCs transduced with IL-4 by LV and transplanted at the onset of EAE were shown to 
be able to reduce the inflammatory immune response by shifting cytokine profile from Th1 to 
Th2 [182]. 
Pig BM-MSCs engineered with IL-4, injected into the inner ear of a guinea pig models of an 
autoimmune inner ear disease were broadly distributed in the inner ear restoring hearing 
function [183]. 
 
Hepatocyte growth factor 
 
Hepatocyte growth factor (HGF) is a multifunctional cytokine involved in organogenesis, 
angiogenesis, cell proliferation, survival and motility. Recently, it has been demonstrated to 
have regenerative properties in myelodegenerative diseases and to be able to improve acute 
GVHD, suggesting that HGF also has immunomodulatory effects [184,185]. It has also been 
shown to act additively with TGF-β to suppress T-cell proliferation in vitro [186]. 
hMSCs express varying amounts of HGF depending on their microenvironment [187]. They 
have been tested in several disease models after transduction with HGF. rBM-MSCs 
transduced with HGF were used in a rat model of liver transplantation and proved to 
significantly reduce graft rejection by decreasing the production of IL-2 and INF-γ and 
increasing IL-4 and IL-10 [188]. hAT-MSCs/ HGF have also been employed for the treatment 
of radiation-induced lung injury, where, again, they were able to reduce secretion of TNF-α, 
IFN-γ, IL-6, TGF-β and increase the expression of IL-10, thus not only reducing 
inflammation but also inhibiting lung fibrosis [189]. hUC-MSCs/HGF were also used for the 
treatment of acute kidney injury in rats, where HGF delivery improved IRI via antiapoptotic 
and antiinflammatory mechanisms, thus providing a novel therapeutic application for hUC-
MSCs in acute kidney injury [190]. 
 
Interleukin-12p40 

























































































































































































































































































































































































Interleukin-12p40 (IL-12p40) homodimer is an antagonist of two potent pro-inflammatory 
cytokines IL-12 and IL-23 [188–190]. The latter are involved in inflammatory bowel disease, 
a chronic disorder of the digestive system that includes Crohn's disease and ulcerative colitis 
[191,192]. 
The effect of MSCs transduced by IL-12p40 has been investigated in dextran sulfate sodium 
salt-induced colitis, an animal model of bowel disease. Injection of Adv/IL-12p40 or 
MSC/IL-12p40 efficiently reduced colitis and tissue damage, thus increasing survival rate. IL-
12p40 reduced both IFN-γ and IL-17 production brought about by IL-12 and IL-23, 
respectively. This effect was more pronounced after MSCs/IL-12p40 than Adv/IL-12p40 
administration [193]. 
 
Interleukin-13, -27, -35 
Interleukin-13 (IL-13) is a pleiotropic cytokine very similar to IL-4 both in structure and 
function [194]. As mentioned above, it is secreted by Th2 lymphocytes and contributes to the 
etiology of allergic reactions. Differently from IL-4, T cells are generally unresponsive to IL-
13 due to the absence of IL-13Ra1 expression on their surface [195]. Allogeneic MSCs 
transduced with IL-13 have been transplanted to modulate allograft-specific immunity in a 
murine model. It has been shown that MSCs/IL-13 injection in muscle and in brain tissue 
prolongs allogeneic cell graft survival [196]. 
Interleukin-27 (IL-27) IL-27 and interleuking-35 (IL-35) are new members of the IL-12 
family. Because of their properties, both of them could be used in the therapy of autoimmune 
diseases. Recently, in vitro works have demonstrated that transduction of hAT-MSC and 
hWJ-MSC with IL-27 and IL-35 does not alter naïve MSC properties [10,197]. 
 
4.2 Enhancing MSC Immunostimulation 
 
MSCs have also been engineered with immunostimulating/proinflammatory cytokines 
mainly for the treatment of different kind of solid tumors. In the following section we 
summarize the results obtained by using the cytokines shown in Table 3. 
 
Interferon-β 
Interferon-β (IFN-β) is a pleiotropic cytokine with a wide range of biological activities such 
as regulation of cell proliferation, innate and adaptive immunity, hematopoiesis, angiogenesis, 
























































































































































































































































































































































































and yet other functions. Most importantly, it can promote tumor regression [198,199]. 
In 2002, Studeny used IFN-β-transduced hBM-MSCs to treat mice bearing human melanoma. 
He demonstrated for the first time that MSCs were integrated into the tumor and released high 
levels of IFN-β in situ. Besides, hBM-MSCs/IFN-β inhibited melanoma growth both in vitro 
and in vivo [8]. This study can be considered a ground-breaker in the field of MSC-based 
tumor-targeted gene therapy, and opened the way to many others studies where MSCs 
engineered with different proinflammatory citokines have been used to suppress solid tumors 




Interleukin-2 (IL-2) is secreted by CD4+ and CD8+ T lymphocytes and NK cells and is 
essential for T-cell proliferation. It is considered a proinflammatory cytokine because it can 
foster expansion of NK cells, CD8+ T cells and T-regs. Because of its immunostimulating 
properties, IL-2 has been tested in immunotherapy against several metastatic tumors. It was 
demonstrated that systemic administration of high doses of recombinant IL-2 in humans 
caused regression of metastatic melanoma, kidney cancer and non-Hodgkin's lymphoma 
[200]; therefore, IL-2 was approved for the treatment of metastatic renal cell carcinoma and 
melanoma by FDA [201–203]. 
To enhance the antitumorigenic effect of IL-2, rBM-MSCs engineered with IL-2 were tested 
in a rat model of glioma. Intracranial injection of such cells prolonged the survival of the 




Interleukin (IL-12) is a powerful activator of NK cells and macrophages. It also skews 
cellular immune responses towards a Th1 response and is produced by DCs and macrophages 
in response to activation [204,205]. IL-12 inhibits tumor growth and prolonges survival of 
different tumor-bearing animals [206,207]. Exogenous IL-12 administrated in phase-I and II 
clinical trials for cancer therapy, induced high levels of IFN-γ and increased susceptibility of 
tumor cells to cytotoxic T lymphocytes. For this reason, it is now considered the main 
antitumoral cytokine [208–210]. 
BM-MSCs engineered with IL-12 were tested in experimental mouse models of melanoma, 
breast tumor, and hepatoma. Results showed that intravenous injection of BM-MSCs/IL-12 
























































































































































































































































































































































































markedly reduced progression of metastases both in midway and late tumor stages, with no 
significant toxicity. The effect observed with BM-MSCs/IL-12 was 10-fold higher than the 
one produced by Adv/IL-12 administration; in addition, the latter failed to favour regression 
of end-stage tumors [211]. Again, BM-MSCs/IL12 were able to migrate into the tumor site 
where they became part of the tumor architecture and released high level of IL-12 thus 
stimulating the immune response inside the tumor. 
In another study, hBM-MSCs engineered with mIL-12 were tested in a mouse xenograft 
model of renal cell carcinoma. Systemic administration of hBM-MSC/mIL-12 reduced renal 
cell carcinoma growth and significantly prolonged mouse survival. Intra-tumor IFN-γ levels 
were significantly higher after hBM-MSC/mIL-12 administration, thus suggesting that IFN-γ 
plays a key role in tumor regression. Furthermore, the observed anti-tumor effect of hBM-
MSC/mIL-12 was mediated by NK cells [212]. In agreement with these results, it was also 
shown that mBM-MSCs/mIL-12 were also effective in the treatment of Ewing’s sarcoma 
[213]. 
hUC-MSCs/IL-12 were evaluated in the SKOV3 experimental model of ovarian cancer. In 
vitro, the supernatant of IL-12-engineered hUC-MSCs was able to significantly inhibit 
proliferation of SKOV3 cells and trigger cellular apoptosis. In vivo, hUC-MSCs/IL-12 
inibited tumor growth in a nude mouse model [214]. 
More recently, a modified form of IL-12 (IL12-M) has been used to transduce rBM-MSCs. 
IL-12M was obtained by N-glycosylation of IL-12 at Asn220. This change reduces secretion 
of the p40 subunit and enhances antigen-specific T-cell responses, without altering IFN-γ 
secretion and IL-12 receptor binding affinity [215]. The effect of rBM-MSCs/IL-12M after 
intratumoral, intravenous and subcutaneous administration was evaluated in two experimental 
models of melanoma and cervical cancer. Pronounced regression of tumors was observed, 
especially after following intratumoral injection, suggesting that this route of administration 
has great relevance in therapy. rBM-MSCs/IL-12M were more efficient than either Adv-IL 
[216]. In a different study, in vitro work suggested the ability of AT-MSC transduced with 
LV/IL-12 to reduce lung adenocarcinoma ability of migration and invasion [217]. 
Taken together, the results from these studies suggest that IL-12-engineered MSC are 
attracted by several tumor microenvironments, where they cause release of release high levels 
of IFN-γ triggering a tumor-specific T-cell response. The antitumor effect is stronger than 
with IL-12 delivered by Adv vectors and the toxicity is significantly lower. 
 


























































































































































































































































































































































































Interleukin-15 (IL-15) is functionally similar to IL-2 but does not stimulate T-reg 
proliferation. However, it does promote long-lasting antitumor T-cell immunity [217–220]. 
Because IL-15 administration has shown antitumor effects in many animal models and in 
human clinical trials [221,222], the effect of hUCB-MSCs transduced with mIL-15 was 
investigated in an experimental model of pancreatic adenocarcinoma, highly resistant to 
chemotherapy. The results showed that UCB-MSCs/mIL-15, systemically infused into 
syngeneic mice bearing Pan02 pancreatic tumors were able to migrate into the tumor site, 
where the secretion of IL-15 fostered activity by both NK and CD8+T cells, thus inhibiting 
tumor growth. Interestingly, mice treated with UCB-MSCs/IL-15 became resistant to Pan02 
pancreatic tumor rechallenge, inferring that MSCs/IL15 were able to augment long-term 




Interleukin-18 (IL-18), also known as IFN-γ-inducing factor, is similar to IL-1 both in 
structure and functionality; it is able to stimulate innate immunity, Th1- and Th2-mediated 
responses and NK activity [224,225]. IL-18 is a potent antitumor cytokine, by inducing tumor 
cell apoptosis and inhibiting tumor angiogenesis [226]. 
IL-18 was shown to favour immune cell migration in gastric cancer and melanoma [227,228]. 
To test its effects on glioma, rBM-MSCs transduced with IL-18 have been tested in vitro and 
in vivo in a glioma-bearing rat model. It was shown that rBM-MSCs/IL-18 inhibited glioma 
growth and prolonged the survival of glioma-bearing rats. The study also showed that the 
antitumor effect of rBM-MSCs/IL-18 is carried out through the enhancement of T-cell 
cytotoxic activity [229]. Unfortunately, complete suppression of tumor growth could not be 
achieved; hence, to extend the efficacy of such treatment, rBM-MSCs were transduced with a 
bicistronic LV vector encoding IL-18 and IFN-β. In this case, inhibition of glioma growth was 
enhanced, demonstrating that IL-18 and IFN-β act sinergistically [230]. 
Finally, the effect of hUC-MSCs/IL-18 was investigated in a model of breast cancer in vitro: 





























































































































































































































































































































































































As an immunostimulating cytokine involved in T and NK cell activation, interleukin-21 (IL-
21) is also able to induce strong cell-mediated immune responses in anti-tumor vaccine 
approaches [233]. It has been tested as therapeutic agent in several animal models of cancer 
and in clinical trials, against tumors such as metastatic lymphoma, melanoma, ovarian cancer, 
and others [233,234]. 
More recently, Il-21-transduced hUC-MSCs (MSCs/IL21) were injected intratumorally in 
mice bearing SKOV3 ovarian cancer. Results showed that hUC-MSCs/IL-21 had potent 
antitumor effects mediated by IL-21 release and upregulation of NK activity through the IFN-
γ and TNF-α secretion [235]. MSCs/IL-21 have also been used in the treatment of B-cell 
lymphoma: MSCs/IL-21 intravenous injected were able to delay tumor incidence and to 




Interleukin-28 (IL-28) belongs to the type III IFN family, together with IFN-λ1, -λ2 and -λ3 
(also known as IL-29), IL-28A and IL-28B [237,238]. It has been shown that type III IFNs 
can exert anti-proliferative activity and promote apoptosis in tumors such as lung and 
esophageal carcinoma [237,239]. Moreover, they proved to not only activate NKs and DCs, 
but also have anti-angiogenetic effects [238,240,241]. 
Recently, hBM-MSCs transduced with IL-28A were tested for their antitumoral activity in 
mice bearing human esophageal carcinoma or colon carcinoma. While naïve hBM-MSCs did 
not display any antiproliferative tumor effect, hBM-MSCs/IL-28A inhibited tumor growth 
and vascularization and stimulated NK activity to a greater extent than IL-28A alone [125]. 
 
Tumor Necrosis Factor-α 
 
Tumor necrosis factor-  (TNF-α) has a pivotal role in the early immune response, it can 
activate both macrophages and neutrophils and is involved in the maturation and activation of 
DCs. It is also a critical cytokine for promoting Th17 cell differentiation. TNF-α and CD40 
ligand (CD40L) have been used to transduce MSCs and the immune-modulatory effects of 
engineered MSCs have been investigated in vitro and in vivo in animal models of human 
breast cancer [242]. 
In vitro results showed that MSCs/TNF-α/CD40L induced proinflammatory responses 
























































































































































































































































































































































































through maturation of DCs, increase of TNF-α, IL-6, and IL-12 levels and reduction of TGF-
β, IL-4, and IL-10 levels, suggesting that they were able to cause a shift toward Th1 profile 
[242]. These results have also been confirmed in vivo, where stimulation of Th1 cytokines and 
inhibition of the Th2 pattern reduced tumor progression to a greater extent than naïve MSCs 
[242]. 
From all these studies, it is evident that MSCs engineered with immunostimulating 
cytokines are more powerful tools for cancer therapy than cytokines alone. All results 
underlined the ability of MSCs to migrate into tumor sites and stimulate release of 
proinflammatory cytokines, which, in turn, prompted a potent cytotoxic effect against cancer 
cells without affecting healthy tissues. It is to emphasize that route of administration of 
engineered MSCs seemed more important than the type of cytokine transduced to obtain the 
best result: indeed, intratumoral injection increased their efficacy, while little difference was 
observed with different cytokines. In addition, MSCs transduced with combined cytokines 
greatly enhanced the results most likely due to the synergistic effect of cytokines. 
An interesting question arising from all these studies concerns the ability of immunoenhanced 
MSCs to keep releasing immunosuppressive factors, such as TGF-β, IDO, PEG-2 and many 
others. Could transduction modify the immunosuppressive profile of MSCs? Since it has been 
shown that transduction of MSCs with viral vectors did not affect MSC properties, we can 
speculate that their ability should not be modified. Nevertheless, the release of pro-
inflammatory cytokines from MSCs could inhibit the production of anti-inflammatory ones in 
an autocrine fashion, and the balance between the pro/anti inflammatory profile of MSCs 
could be tipped in favor of the pro-inflammatory one also in the presence of pro-inflammatory 
stimuli. This point was not investigated in the works examined, and the question is open and 
deserves further insight. 
Stability and duration over time of the pro-inflammatory cytokines production depend on the 
method of transduction used. As said above, LVs guarantee a long-lasting transgene 
expression compared to the ADV and AAV because of the integration of the transgene in the 
genome. However, most of the work revised in this review does not address the issue of 
duration expressly. 
 
5. Future outlook 
 
One of the main goals of regenerative and personalized medicine is the development of 
cellular therapies free of side effects, and devoid of ethical concerns. MSCs were found to be 
























































































































































































































































































































































































suitable and promising candidates, as demonstrated by the remarkable results obtained in 
numerous clinical trials. Although the vectors alone are being used in various clinical settings 
and preclinical studies showed that MSC transduction is safe and can enhance therapeutic 
potential compared to naïve MSCs, no clinical trials have yet been performed with engineered 
MSCs. 
Large-scale application of engineered MSCs for cell therapy requires a high number of cells 
readily available; this obstacle could be overcome by implementation of small-scale 
bioreactors that have proved adeguate to obtain large numbers of clinical grade MSCs [243]. 
Another new promising source of MSCs are inducible pluripotent stem cells that can be 
reprogrammed into MSCs, making it possible to derive autologous MSCs from uninvasive 
biopsies (e.g. skin biopsy)[244]. This derivation also solves troubles with the aged patient, 
who carries BM-MSCs with significantly reduced survival and differentiation potential: in 
contrast, using human iPSCs can generate indefinitely fresh MSCs. The only caveat seems 
their reduced adipogenic differentiation [245]. In addition, small-scale bioreactors have also 
proved effective at expanding pluripotent stem cells [246], making clinical trials with 
inducible pluripotent stem cells -derived MSC accessible to small laboratories. 
Viral vector manufacturing is quickly moving from plates to bioreactors, with advantages in 
terms of costs, standardization, and biosafety [247]. This shift will facilitate genetic 
engineering to move from bench to bedside. As new generation, safer viral vectors have come 
of age as a therapeutic tool, with, as mentioned, the European Medicines Agency approving 
the first gene therapy using an AAV vector to treat lipoprotein lipase deficiency (Glybera
®
) in 
2012. Furthermore, recent data from three clinical trials of gene therapy for hemophilia B are 
very encouraging [248]. These examples and many more undergoing gene therapy trials are 
increasing expectations of gene therapy at bedside. 
However, with the first gene therapy now licensed and priced at around US$1 million per 
patient, cost and uncertain funding mechanisms present a potential barrier to patient access. 
Mixing advances in gene transfer and manipulation (e. g. gene editing) with advances in 
pluripotent stem cell reprogramming (e.g. non-integrative reprogramming and bench 
bioreactors), and large-scale production and cost/reimbursement optimization will likely 
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Figure 1. Schematic of adenoviral (Adv) and lentiviral (LV) vector genomes. A. Parental Adv isolate, usually of 
serotype 2 or 5, is deleted of most early (indicated with an E and light blue) genes and other regulatory genes and 
retain most structural genes, major late promoter (MLP, shown in grey) and inverted terminal repeats (ITR, 
terminal promoters, shown in grey). Transgene (light green) and its eukaryotic promoter (EP, shown in yellow) 
replace E1A/E1B genes. B. To minimize risks of generating infectious particles, the third generation vector is 
produced with the viral genes provided by four separated constructs. The vector genome showed here is a self-
inactivating type that is obtained by deleting the U3 region of 5’LTR (shown in grey); U3 deletion abolishes 
5’LTR promoter activity and is transferred to 3’LTR during reverse transcription. From the parental genome, the 
vector retains the encapsidation signal (psi), the Rev-responsive element (RRE) necessary for Rev-driven 
nuclear-cytoplasmic exportation of viral messenger RNAs, and the central poly-purine tract (cPPT). It also 
contains the woodchuck hepatitis post-transcriptional regulatory element (WPRE) that increases efficiency of 
vector RNA encapsidation and post-transcriptional processing of transgene RNA, respectively. The EP placed 
upstream of 5’LTR drives expression of the genome construct as well as of the three other constructs. The 
packaging construct encodes capsid and enzyme proteins and lacks encapsidation signal. Rev and envelope 
proteins are provided in trans with remaining two DNA plasmids. 
























































































































































































































































































































































































Table 1. Pros and cons of adenoviral, adeno-associated, and lentiviral vectors 
 
Adenoviral Adeno-associated Lentiviral 
Advantages   
Transduce non-dividing and dividing 
cells 
Transduce non-dividing and dividing cells Transduce non-dividing and dividing cells 
Carry up to 8 Kbp heterologous DNA Parental virus apathogenic Carry up to 9 Kbp heterologous DNA 
High and short-term transgene 
expression 
Wide cellular tropism High and long-term transgene expression 
Fast and high titer production Potential site-specific integration Stable transduction  
Good oncolytic and vaccine vector Low immunogenic Easy to re-target and produce 
Disadvantages 
  
Highly immunogenic Carry up to 5 Kbp heterologous DNA Risk of insertional mutagenesis 
High levels of pre-existing immunity High titer preparations difficult to obtain High titer preparations difficult to obtain 
The genome persists as episome and is 
not transmitted to progeny cells 
Current vectors are unable to integrate their 
genome into host cell genome 
Incorporation of some viral regulatory 
proteins in vector particles 
Transient expression of the transgene Production requires co-infection by a helper 
virus 
Transient expression of the transgene with 
integration-defective vector 
 

















































































































































































































































































































































































































































































































































































































































































































































































Table 2: MSCs engineered with anti-inflammatory cytokines  
MSC 
source 











apoptosis of islet 

































IL-4 ASNHL** guinea pig 
model  













IL-10 In vitro study Evaluate the 





































IFN-γ and TNF-α 
secretion 
[9]  














































































































































































































































































































































































































IL-27 In vitro  Transduction of 










IL-35 In vitro  Transduction of 










HGF Liver transplantation in rat  Prevention of liver 
allograft rejection  
Reduction of 
graft rejection, 
decrease of IL-2 
and INF-γ and 
increase of IL-4 




HGF Rat model of IRI-induced 
kidney injury 








HGF Mouse model  











* non-obese diabetic/severe combined immunodeficiency 
**Autoimmune sensorineural hearing loss 





























































































































































































































































































































































































Table 3: MSC engineered with pro-inflammatory cytokines 
MSC 
source 




Melanoma bearing mice To transduce SC 






rBM-MSC IL-2 rat model of glioma Glioma therapy Reduction of 
tumor mass 
[106] 
mBM-MSC IL-12 experimental model of animal 
bearing melanoma, breast 
tumor, and hepatoma 
Cancer therapy Reduction of 
tumor mass and 
metastases 
[211] 





tumor growth  
[213] 














rBM-MSC IL-12 melanoma and cervical cancer 
experimental models 
Antitumor activity Reduction of 
tumor mass and 
metastases 
[252] 





of A549 cell 
[217] 


























tumor growth and 
immunitation 
[223] 
rBM-MSC IL-18 rat glioma model Glioma Therapy Partial inhibiton 
of Glioma growth 
[229] 
hUC-MSC IL-18 In vitro study Assessment of anti- HUC-MSCs/IL- [231-232] 
























































































































































































































































































































































































breast cancer activity 
of MSC/IL-18 







Intracranial glioma rat model Glioma therapy Inhibiton of 
Glioma growth 
[230] 





, upregulation of 
NK, IFN-γ and 
TNF-α 
[235] 










In vitro study assess anti-tumor 
effect on human lung 
carcinoma cells of 
MSC/IL-28A 
Inhibition of  






Mouse breast cancer model Breast Cancery 
Therapy 
Inhibition of 
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